ERGOMAR

Post-LOE

ergotamine tartrate

TerSera Therapeutics

ANDASUBLINGUALTABLET

Approved

Sep 1992

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

ERGOMAR (ergotamine tartrate) by TerSera Therapeutics is clinical pharmacology: ergotamine is an alpha adrenergic blocking agent with a direct stimulating effect on the smooth muscle of peripheral and cranial blood vessels and produces depression of central vasomotor centers. Approved for migraine. First approved in 1992.

Drug data last refreshed 21h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY: Ergotamine is an alpha adrenergic blocking agent with a direct stimulating effect on the smooth muscle of peripheral and cranial blood vessels and produces depression of central vasomotor centers. The compound also has the properties of serotonin antagonism. In comparison to…

Indications (1)

migraine

Worked on ERGOMAR at TerSera Therapeutics? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.